March 1, 2018 / 1:16 PM / 3 months ago

BRIEF-Idera Pharma Announces Launch Of Phase 3 Trial Evaluating IMO-2125 In Combination With Ipilimumab

March 1 (Reuters) - Idera Pharmaceuticals Inc:

* IDERA PHARMACEUTICALS ANNOUNCES LAUNCH OF GLOBAL PHASE 3 TRIAL EVALUATING IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ANTI-PD-1 REFRACTORY MELANOMA (ILLUMINATE 301) Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below